Recruiting Clinical Trials

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

By April 24, 2017 No Comments

Condition

Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface|Malignant Peritoneal Mesothelioma|Peritoneal Carcinomatosis

Estimated Enrollment: 168

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: 12-110|5P01CA132714-05

Study First Received: May 28, 2014

Last Updated: February 2, 2017

Estimated Primary Completion Date: December 2017

 

Primary Outcome Measures:

Number of participants with adverse events|Time to disease progression|How long participants live after surgery|Changes in the immune system

Sponsors and Collaborators:

Pawel Kalinski|National Cancer Institute (NCI)|University of Pittsburgh

Website Link: https://ClinicalTrials.gov/show/NCT02151448

Leave a Reply

Call Now